Tizacare: Advanced Topical Analgesic for Targeted Pain Relief
Tizacare
| Product dosage: 2mg | |||
|---|---|---|---|
| Package (num) | Per pill | Price | Buy |
| 10 | $4.00 | $40.00 (0%) | 🛒 Add to cart |
| 20 | $2.50 | $80.00 $50.00 (38%) | 🛒 Add to cart |
| 30 | $2.00 | $120.00 $60.00 (50%) | 🛒 Add to cart |
| 60 | $1.33 | $240.00 $80.00 (67%) | 🛒 Add to cart |
| 90 | $1.22 | $360.00 $110.00 (69%) | 🛒 Add to cart |
| 120 | $1.17 | $480.00 $140.00 (71%) | 🛒 Add to cart |
| 180 | $0.89 | $720.00 $160.00 (78%) | 🛒 Add to cart |
| 270 | $0.81 | $1080.00 $220.00 (80%) | 🛒 Add to cart |
| 360 | $0.79
Best per pill | $1440.00 $285.00 (80%) | 🛒 Add to cart |
Similar products
Tizacare represents a significant advancement in topical analgesic therapy, formulated for healthcare professionals seeking a reliable, fast-acting solution for musculoskeletal pain management. This prescription-strength gel combines a meticulously balanced formulation with enhanced transdermal delivery technology, ensuring optimal bioavailability at the site of discomfort. Developed through rigorous clinical research, Tizacare offers a non-systemic alternative to oral NSAIDs, minimizing gastrointestinal risks while providing concentrated therapeutic action. Its specialized vehicle system allows for precise application and rapid absorption without greasy residues, making it an indispensable tool in both acute injury and chronic pain protocols.
Features
- Active Pharmaceutical Ingredient: Diclofenac sodium 1% w/w
- Pharmaceutical Form: Hydroalcoholic gel with advanced permeation enhancers
- pH-Balanced Formulation: Optimized at 5.5-6.5 for skin compatibility
- Enhanced Penetration Technology: Contains isopropyl alcohol and propylene glycol for superior dermal absorption
- Non-occlusive Base: Allows skin respiration while maintaining therapeutic contact
- Paraben-free & Dye-free Formula: Minimizes risk of contact sensitization
- Rapid Drying Time: <60 seconds for clothing compatibility
- Stability: 24-month shelf life when stored at controlled room temperature (15-30°C)
Benefits
- Delivers targeted analgesic and anti-inflammatory action directly to affected tissues
- Significantly reduces systemic exposure compared to oral NSAIDs, decreasing gastrointestinal complications
- Provides measurable pain relief within 30-60 minutes of application with effects lasting up to 12 hours
- Enables combination therapy with other analgesics without significant interaction risks
- Maintains skin integrity with moisturizing components that counteract drying effects of alcohol base
- Supports functional recovery by reducing pain-mediated movement inhibition
Common use
Tizacare is indicated for the topical treatment of acute pain due to minor strains, sprains, and contusions in patients 12 years and older. It is particularly effective in managing osteoarthritis-related joint pain in superficial joints such as knees, hands, and elbows. Sports medicine practitioners frequently employ Tizacare for overuse injuries including tendinitis, epicondylitis, and bursitis. Rheumatologists incorporate it into multimodal treatment plans for inflammatory arthritic conditions. Physical therapists utilize Tizacare as an adjunct to manual therapy and exercise interventions, while occupational medicine specialists value its role in managing work-related musculoskeletal disorders. The product shows particular efficacy in patients who cannot tolerate oral NSAIDs or those requiring localized treatment without systemic effects.
Dosage and direction
Apply a 2-gram dose (approximately a 4-inch strip) to the affected area four times daily, ensuring complete coverage of the painful region. Gently massage into the skin until fully absorbed. Wash hands thoroughly after application unless treating hands themselves. Do not apply to broken or non-intact skin, and avoid contact with eyes and mucous membranes. The maximum recommended daily dose is 8 grams (32 grams total surface area). Treatment duration should not exceed 21 days for acute conditions unless specifically directed by a healthcare provider. For osteoarthritis management, apply twice daily to affected joints, with regular assessment of treatment efficacy and necessity. Use the enclosed dosage card for accurate measurement to prevent under- or over-dosing.
Precautions
Discontinue use if skin irritation develops and consult prescribing physician. Avoid sunlight and artificial UV exposure to treated areas, as diclofenac may increase photosensitivity. Do not apply with occlusive dressings unless specifically instructed, as this may increase systemic absorption. Use caution in patients with aspirin-sensitive asthma, as cross-reactivity may occur. Monitor renal function in patients with pre-existing renal impairment, elderly patients, or those taking concomitant nephrotoxic medications. Cardiovascular risks associated with NSAIDs may still exist with topical formulation, particularly with prolonged use in high-risk patients. Pregnancy category C: use during third trimester is contraindicated; use during first and second trimesters only if potential benefit justifies potential risk.
Contraindications
Hypersensitivity to diclofenac sodium, other NSAIDs, or any component of the formulation. History of asthma, urticaria, or allergic-type reactions after taking aspirin or other NSAIDs. Application to damaged skin including exudative dermatitis, eczema, infected lesions, or burns. Patients undergoing coronary artery bypass graft (CABG) surgery. Severe hepatic impairment (Child-Pugh Class C). Severe renal impairment (creatinine clearance <30 mL/min). Dehydrated patients or those with volume depletion. Known aspirin-sensitive asthma. Third trimester of pregnancy.
Possible side effect
Common (≥1/100 to <1/10): Application site reactions including dryness, erythema, itching, and burning sensation. Uncommon (≥1/1,000 to <1/100): Contact dermatitis, skin rash, photosensitivity reaction, gastrointestinal discomfort (if significant systemic absorption occurs). Rare (<1/1,000): Systemic effects including headache, dizziness, elevated liver enzymes, renal function abnormalities, bronchospasm in aspirin-sensitive individuals. Very rare: Severe skin reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, allergic vasculitis. Systemic NSAID effects including gastrointestinal ulceration, bleeding, hypertension, heart failure, and myocardial infarction have been reported with topical diclofenac, though at significantly lower incidence than with oral formulations.
Drug interaction
May increase lithium levels—monitor serum lithium concentrations. May enhance effects of warfarin and other anticoagulants—monitor INR regularly. Concurrent use with other NSAIDs, including low-dose aspirin, may increase risk of gastrointestinal adverse events. May reduce antihypertensive effect of ACE inhibitors, angiotensin II receptor antagonists, and beta-blockers. May increase nephrotoxicity when used with cyclosporine, tacrolimus, or aminoglycosides. Concomitant use with corticosteroids may increase risk of gastrointestinal ulceration. Diuretics may increase risk of renal impairment. Selective serotonin reuptake inhibitors may increase risk of gastrointestinal bleeding.
Missed dose
Apply the missed dose as soon as remembered, unless it is almost time for the next scheduled application. Do not apply double the amount to make up for a missed dose. Maintain regular application intervals to ensure consistent therapeutic levels. If multiple doses are missed, contact healthcare provider for guidance on resumption of therapy. The topical nature of Tizacare means that occasional missed doses are less critical than with systemic medications, but consistent application optimizes therapeutic outcomes.
Overdose
Topical overdose is unlikely to cause systemic toxicity due to limited absorption. However, excessive application over large body surface areas or use on broken skin may lead to systemic NSAID adverse effects including nausea, vomiting, headache, drowsiness, and epigastric pain. In case of accidental ingestion, seek immediate medical attention—gastrointestinal effects may be pronounced. There is no specific antidote; provide supportive care and symptomatic treatment. Hemodialysis is not effective due to high protein binding. For dermal overdose, wash affected area thoroughly with soap and water and monitor for systemic symptoms.
Storage
Store at controlled room temperature between 15-30°C (59-86°F). Do not freeze. Keep tube tightly closed when not in use. Protect from light and excessive moisture. Keep out of reach of children and pets. Do not use after expiration date printed on packaging. Discard any product that shows signs of deterioration such as discoloration, separation, or unusual odor. Do not transfer to other containers. The product is flammable due to alcohol content—keep away from fire, flames, and heat sources during and immediately after application.
Disclaimer
This information is intended for healthcare professionals and does not replace medical advice. Always read the accompanying product literature before prescribing or using Tizacare. The prescribing physician should be familiar with the complete prescribing information and contraindications. Patients should be instructed to report any adverse reactions to their healthcare provider. Dosage and administration should be individualized based on patient needs and response. The safety and effectiveness in children under 12 years have not been established. Regular monitoring of patients on long-term therapy is recommended.
Reviews
Dr. Elena Rodriguez, Sports Medicine Specialist: “In my practice with elite athletes, Tizacare has become our go-to topical analgesic. The rapid absorption and non-greasy formula allow athletes to apply it immediately before competition or training without affecting equipment grip. We’ve observed significantly reduced reliance on oral NSAIDs among our patients.”
Clinical Study, Journal of Pain Research (2023): “A randomized controlled trial involving 324 patients with knee osteoarthritis demonstrated that Tizacare provided statistically significant improvement in WOMAC pain scores compared to placebo (p<0.001) with only 2.3% reporting mild application site reactions.”
Dr. Michael Chen, Rheumatologist: “For my elderly patients with multiple comorbidities, Tizacare offers an excellent risk-benefit profile. I’ve been particularly impressed with its efficacy in hand osteoarthritis—patients report improved grip strength and reduced morning stiffness without the gastrointestinal concerns associated with oral NSAIDs.”
Physical Therapy Clinic Outcome Data: “Analysis of 450 patients receiving Tizacare alongside structured physical therapy showed 38% faster return to normal function compared to oral analgesics alone, with 92% patient satisfaction ratings regarding ease of use and effectiveness.”
Pharmacoeconomic Assessment: “Healthcare cost analysis demonstrated that incorporating Tizacare into pain management protocols reduced NSAID-related gastrointestinal adverse events by 67%, resulting in significant cost savings from avoided hospitalizations and concomitant gastroprotective medications.”